GALDERMA GROUP AG (NYSE: GALDY) — Perfil da empresa, notícias e dados financeiros
GALDERMA GROUP AG is a Switzerland-based pure-play dermatology company specializing in research, development, and commercialization of skin care solutions across three core product categories: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology.
GALDERMA GROUP AG
GALDERMA GROUP AG is a Switzerland-based pure-play dermatology company specializing in research, development, and commercialization of skin care solutions across three core product categories: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Its commercial portfolio includes hyaluronic acid dermal fillers, neuromodulators, biostimulators, daily skin health products, and prescription treatments for dermatological conditions such as acne, rosacea, atopic dermatitis, and psoriasis. Operating globally with dedicated research and development centers and manufacturing facilities in Europe, North America, and South America, the organization distributes its therapeutic and aesthetic products across more than ninety countries to consumers and healthcare professionals.
Resumo
Operações
Produtos e/ou serviços de GALDERMA GROUP AG
- Injectable Aesthetics - Dermal Fillers and Biostimulators: Formulates and manufactures hyaluronic acid dermal fillers and poly-L-lactic acid biostimulators, including Restylane and Sculptra, designed for facial aesthetic restoration, tissue volume enhancement, and collagen stimulation distributed across global markets.
- Injectable Aesthetics - Neuromodulators: Produces botulinum toxin type A injectable treatments, such as Dysport, Alluzience, and Relfydess, supplying specialized clinics and healthcare professionals worldwide for temporary smoothing of moderate-to-severe glabellar lines and facial dynamic wrinkles.
- Dermatological Skincare - Dermo-Cosmetics: Develops, manufactures, and distributes scientifically formulated daily cleansers, moisturizers, and sun protection lines, including Cetaphil and Alastin Skincare, catering to sensitive, damaged, and post-procedure skin across retail and clinical channels globally.
- Therapeutic Dermatology - Topical Acne and Rosacea Therapies: Provides prescription topical dermatological formulations, including Differin, Epiduo, Soolantra, and Aklief, targeting inflammatory skin conditions, acne vulgaris, and rosacea through widespread distribution networks in hospitals, pharmacies, and specialty dermatology clinics.
- Therapeutic Dermatology - Biologics and Immuno-Dermatology: Commercializes targeted monoclonal antibody biological therapies, including Nemluvio, for chronic inflammatory skin disorders such as moderate-to-severe atopic dermatitis and prurigo nodularis, expanding clinical treatments across major pharmaceutical markets globally.
- Global Manufacturing and Research Infrastructure: Operates specialized pharmaceutical manufacturing plants and R&D centers located in Alby in Sweden, Baie-D'Urfé in Canada, Hortolândia in Brazil, and Zug in Switzerland, producing sterile injectables, topical creams, gels, and liquids.
equipe executiva do GALDERMA GROUP AG
- Flemming OrnskovCEO & Director
- Luigi Felice La CorteChief Financial Officer
- Adrian MurphyHead of Global Operations
- Emil IvanovHead of Strategy, Investor Relations & ESG
- Nakisa SerryGeneral Counsel, Chief Compliance Officer & Interim CHRO
- Christian MarcouxChief Communications Officer
- Desislava LazarovaGlobal Head of Customer Education & Training
Histórico de dividendos
Dividendos por ação pagos pela GALDERMA GROUP AG, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $0.0666 |
| FY2025 | — | — | — | $0.0206 |
Principais indicadores financeiros
Resultados divulgados pela GALDERMA GROUP AG, em USD.
- Cap. de mercado
- 52,3 bi
- Receita (TTM)
- 5,9 bi
- P/L
- 61.5
- LPA (diluído, TTM)
- 0.7
- Dividend yield
- 0.2%
- Margem de lucro
- 14.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 5,2 bi | 876 mi | 613 mi | |
| 4,4 bi | 678 mi | 231 mi | |
| 4,1 bi | 611 mi | -57 mi | |
| 3,8 bi | 406 mi | -98,5 mi |